Abstract
Toxicoproteomics is the study of the effects of chemical exposure on tissues through identification and quantitative evaluation of changes occurring in the proteome profile. This approach has been and continues to be applied in the preclinical testing of drugs for precise as well as high-throughput determination of toxic effects. Several investigations have indicated that use of proteomics can lead to successful identification of potentially toxic compounds earlier in the drug development process. This review covers recent studies that have used simultaneous measurement of multiple protein markers for prediction of tissue toxicities. In addition, conventional and newer proteomic techniques have been evaluated for applicability to drug toxicology studies. The potential of toxicoproteomics to predict adverse drug reactions in clinical use have also been explored.
Keywords: proteomics, toxicoproteomics, drug toxicology, personalized medicine, hepatotoxicity, nephrotoxicity
Current Proteomics
Title: Toxicoproteomics: Applications in Drug Development
Volume: 2 Issue: 2
Author(s): N. Gupta, A. Law, R. Poddar, M. Louie, A. Ray and D. N. Chakravarti
Affiliation:
Keywords: proteomics, toxicoproteomics, drug toxicology, personalized medicine, hepatotoxicity, nephrotoxicity
Abstract: Toxicoproteomics is the study of the effects of chemical exposure on tissues through identification and quantitative evaluation of changes occurring in the proteome profile. This approach has been and continues to be applied in the preclinical testing of drugs for precise as well as high-throughput determination of toxic effects. Several investigations have indicated that use of proteomics can lead to successful identification of potentially toxic compounds earlier in the drug development process. This review covers recent studies that have used simultaneous measurement of multiple protein markers for prediction of tissue toxicities. In addition, conventional and newer proteomic techniques have been evaluated for applicability to drug toxicology studies. The potential of toxicoproteomics to predict adverse drug reactions in clinical use have also been explored.
Export Options
About this article
Cite this article as:
Gupta N., Law A., Poddar R., Louie M., Ray A. and Chakravarti N. D., Toxicoproteomics: Applications in Drug Development, Current Proteomics 2005; 2 (2) . https://dx.doi.org/10.2174/1570164054494181
DOI https://dx.doi.org/10.2174/1570164054494181 |
Print ISSN 1570-1646 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6247 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Local Recurrence vs Radiotherapy-Induced Edema in Advanced Laryngeal Carcinoma: Is FDG PET/CT Up to the Challenge?
Current Molecular Imaging (Discontinued) Search for New and Novel Chemotherapeutics for the Treatment of Human Malignancies
Mini-Reviews in Medicinal Chemistry Therapeutic Benefits of <i>Piper nigrum</i>: A Review
Current Bioactive Compounds Molecular Markers of Glioblastoma and the Potential for Integration with Imaging: the Future for Assigning Prognosis and Best Treatment Strategy
Current Molecular Imaging (Discontinued) Image-Guided Nanoparticle-Based siRNA Delivery for Cancer Therapy
Current Pharmaceutical Design Targeting mTOR: Evaluating the Therapeutic Potential of Resveratrol for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Natural Products Based Anticancer Agents
Mini-Reviews in Organic Chemistry Poly(lactic acid)-poly(ethylene oxide) Block Copolymers: New Directions in Self-Assembly and Biomedical Applications
Current Medicinal Chemistry Periodontal Disease and Potential Association with Systemic Diseases and Conditions (Mini-review)
Applied Clinical Research, Clinical Trials and Regulatory Affairs Tumor Necrosis Factor-α, a Regulator and Therapeutic Agent on Breast Cancer
Current Pharmaceutical Biotechnology Identification of Novel Key Targets and Candidate Drugs in Oral Squamous Cell Carcinoma
Current Bioinformatics Glucans as Biological Response Modifiers
Endocrine, Metabolic & Immune Disorders - Drug Targets Design and Virtual Screening Towards Synthesis of Novel Substituted Thiosemicarbozones as Ribonuleotide Reductase (RNR) Inhibitors with Improved Cellular Trafficking and Anticancer Activity
Current Topics in Medicinal Chemistry Induction of Humoral and Cellular Immune Responses in Mice by Multiepitope Vaccines Composing of Both T and B Lymphocyte Epitopes of MAGE-A3 which are Recombined into HBcAg
Protein & Peptide Letters Preface:
Recent Patents and Topics on Imaging (Discontinued) Therapy of Hepatocellular Carcinoma with Rhenium-188 Lipiodol
Current Radiopharmaceuticals Off-Label Use of Sunitinib in Patients with Advanced, Epithelial Thyroid Cancer: A Retrospective Analysis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Editorial (Thematic Issue: Gene Therapy for Fanconi Anemia Enters a New Clinical Era)
Current Gene Therapy Phenolic Compounds in Prevention and Treatment of Skin Cancers: A Review
Current Medicinal Chemistry Enhanced Analytic Approach for Describing pH Triggered Fast Drug Release Systems
Current Drug Delivery